Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TransMedics (TMDX) EBIT (2018 - 2026)

TransMedics has reported EBIT over the past 8 years, most recently at -$64.7 million for Q4 2025.

  • For Q4 2025, EBIT fell 848.84% year-over-year to -$64.7 million; the TTM value through Dec 2025 reached $22.6 million, down 39.78%, while the annual FY2025 figure was $22.6 million, 39.78% down from the prior year.
  • EBIT for Q4 2025 was -$64.7 million at TransMedics, down from $23.3 million in the prior quarter.
  • Over five years, EBIT peaked at $36.6 million in Q2 2025 and troughed at -$64.7 million in Q4 2025.
  • A 5-year average of -$2.0 million and a median of -$3.8 million in 2022 define the central range for EBIT.
  • Biggest five-year swings in EBIT: skyrocketed 1480.57% in 2024 and later tumbled 848.84% in 2025.
  • Year by year, EBIT stood at -$11.3 million in 2021, then surged by 40.16% to -$6.8 million in 2022, then surged by 138.4% to $2.6 million in 2023, then surged by 232.08% to $8.6 million in 2024, then tumbled by 848.84% to -$64.7 million in 2025.
  • Business Quant data shows EBIT for TMDX at -$64.7 million in Q4 2025, $23.3 million in Q3 2025, and $36.6 million in Q2 2025.